Affimed Announces Annual General Meeting of Shareholders
July 10 2020 - 6:30AM
Heidelberg, Germany, July 10, 2020 –
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology
company committed to giving patients back their innate ability to
fight cancer, announced today that the Annual General Meeting of
Shareholders will be held on Tuesday, August 4, 2020 at the
Sheraton Amsterdam Airport Hotel and Conference Center, Schiphol
Boulevard 101, 1118 BG Schiphol, Netherlands. The meeting will
start at 11:00 a.m. CET.
The notice and agenda of the general meeting are available in
the Investor Relations section under “Notice to convene the Annual
General Meeting of Shareholders of Affimed N.V.” of Affimed’s
website at https://www.affimed.com/investors/ as well as the
SEC’s website at www.sec.gov.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology
company committed to giving patients back their innate ability to
fight cancer. Affimed’s fit-for-purpose ROCK® platform allows
innate cell engagers to be designed for specific patient
populations. The company is developing single and combination
therapies to treat hematologic and solid tumors. The company is
currently enrolling patients into a registration-directed study of
AFM13 for CD30-positive relapsed/refractory peripheral T cell
lymphoma and into a Phase 1/2a dose escalation/expansion study of
AFM24 for the treatment of advanced EGFR-expressing solid tumors.
For more information, please visit www.affimed.com.
Affimed Investor Contact:
Alex Fudukidis Head of Investor Relations E-Mail:
IR@affimed.com
Tel.: +1 (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024